Minodronic acid

Drug Profile

Minodronic acid

Alternative Names: Bonoteo Tablets; Minodron; Minodronate; ONO-5920; Onobis®; Recalbon Tablets; YH 529; YM 529

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Ono Pharmaceutical
  • Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteoporosis
  • Discontinued Cancer metastases; Hypercalcaemia; Multiple myeloma

Most Recent Events

  • 31 Aug 2017 Ono Pharmaceutical suspends patient enrolment in a phase II trial for Osteoporosis in Japan (PO) (UMIN000021242)
  • 16 Sep 2016 Pharmacokinetics data from preclinical studies in Osteoporosis was presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2016)
  • 16 Sep 2011 Launched for Osteoporosis (intermittent therapy) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top